e games examples
e games examples
Rep. Sean Casten joins The LeadEastman Chemical CEO Mark Costa sells $1.9 million in stockSadness as iconic Dublin pub that featured in Love/Hate is set to be demolished
Shares of Bank of America (BAC) fell over 1% on Monday after the Office of the Comptroller of the Currency (OCC) issued a cease-and-desist order against the lender for failing to timely file suspicious activity reports and correct a previously identified deficiency related to its customer due diligence processes. The OCC said the order also identifies deficiencies in the lender's BSA compliance program's internal controls, governance, independent testing, and training components. The bank has neither admitted nor denied the findings of the OCC. However, a Bank of America representative told Bloomberg in an emailed statement that the bank has been working closely with the Office of the Comptroller of the Currency over the past year to improve its anti-money-laundering and sanctions programs. “The work we’ve done so far positions us well to implement the requirements of the consent order.” The OCC order requires the lender to take comprehensive corrective actions to enhance its BSA/anti-money laundering (AML) and sanctions compliance programs. This includes hiring an independent consultant to assess these programs and conduct look-back reviews to ensure all suspicious activity was appropriately reported. Following the announcement by OCC, retail sentiment on Stocktwits dipped into the ‘bearish’ territory (44/100) from ‘neutral’ a day ago. Most retail chatter on Stocktwits indicated a negative bias toward the stock. Earlier this month, Morgan Stanley downgraded the shares of Bank of America to ‘Equal Weight’ from ‘Overweight’ while raising its price target to $55 from $48, according to The Fly. The brokerage expects a more balanced risk-reward and prefers money centers with a higher skew to capital markets. Meanwhile, shares of BAC have gained over 28% since the beginning of the year. For updates and corrections, email newsroom[at]stocktwits[dot]com. Robbins LLP Urges WOLF Stockholders with Large Losses to Contact the Firm for Information About the Wolfspeed, Inc. Class Action Lawsuit321 crore project to boost Dibrugarh’s flood defence The year of ‘brain rot’PSG win again to retain lead over second-placed MonacoArkansas WR Andrew Armstrong declares for NFL draft, skipping bowl EAST RUTHERFORD, N.J. -- An emotional Daniel Jones spoke for the first time since being benched by the New York Giants in favor of Tommy DeVito and expressed regret for not producing enough victories, while also saying he's still processing his future. Jones has been the Giants' starting quarterback for much of the past six years. That changed Monday when he was informed of the decision by coach Brian Daboll and general manager Joe Schoen that there would be a change at quarterback. Jones came to Thursday's news conference with a prepared statement in which he thanked the team but also articulated his disappointment. Editor's Picks DeVito 'sticking to football,' trying to avoid hoopla 23h Jordan Raanan Giants demote Jones to QB3, tab DeVito to start 3d Jordan Raanan Latest NFL Week 12 buzz: What we're hearing on Daniel Jones' benching, GM candidates and playoff races 1d Dan Graziano and Jeremy Fowler "There have been some great times, but of course we all wish there had been more of those," Jones said as part of his statement. "I take full responsibility for my part in not bringing more wins. Nobody wanted to win more games worse than me and I gave everything I had on the field and in my preparation. Of course, this season has been disappointing for all and of course I wish I could have done more. I'm 100% accountable for my part. I did not play well enough consistently enough to help the team get results. "The reality of the NFL is it's hard to win games. It requires consistent performance for everyone involved. We didn't do that well enough, so the idea to change something happens and I understand. I love the game, I love being part of the team. I'm excited for the next opportunity. I know there is a lot of good football in front of me and I'm excited about that." That next opportunity could come elsewhere relatively soon. Jones, who has thrown eight touchdown passes with seven interceptions this season, was noncommittal when asked whether he would stay with the Giants for the rest of the season. New York (2-8) has seven games left. "That's something I'm processing," Jones said. "Right now, my focus is on how I can help all these guys, help all these guys prepare for this week." Jones, 27, said he wanted to find a way to keep playing and tried to create a situation that made both sides comfortable despite a $23 million injury guarantee for next season. It was too late. New York's brass had already decided it was time to move on from the 2019 No. 6 pick as their starting quarterback and turn to DeVito, a second-year quarterback who won three games as a starter last season. The Giants explained the decision to Jones as there being a need for change with the team at 2-8. He admittedly was not happy, as it effectively will end his career with the team that drafted him out of Duke University. The injury guarantee was also part of the equation. "That was a piece of the conversation, for sure," Jones said. "I wanted to play. I wanted to play badly and do what I could to play. I think it was a part of it. Most of those discussions took place with my agents and [general manager Joe Schoen]." The Giants have lost five straight games, and Jones is 3-13 as the starter since signing a four-year, $160 million deal in March 2023. That prompted the switch, even if it wasn't Jones' preference. "Definitely not happy about it. Not what you want to hear. All those emotions you have," he said. "At the end of the day, this is football and we're in a business where you're expected to get results, and we weren't doing it. You've got to accept it and understand." Jones has been the fourth quarterback this week for the Giants behind DeVito, Drew Lock and the recently signed Tim Boyle . He spent part of Thursday's practice as a scout team safety during a walk-through period. It's a situation that Lock said was weird seeing at practice. "Well, I've got the injury guarantee. So, that's that," Jones said. "I understand it. They don't want to take any risks. At that point, it's just do as you're told." The Giants would be on the hook for $23 million should Jones sustain a serious injury and not be able to pass a physical early next year. It's a risk the Giants are not willing to take given the circumstances. As for going home (such as what happened with Derek Carr two years ago in Las Vegas) or asking for his outright release, both options still seem to be still in play for Jones. "Like I said, I'm still processing and trying to think through what the best thing is for this team, what the best thing is for me," he said. In the meantime, he's also processing it all coming to an end. Admittedly, it hasn't been easy. Tears started to well in Jones' eyes when asked about the support he has received in recent days from teammates, specifically 2019 draftmates Dexter Lawrence and Darius Slayton . "Like I said, I've created a lot of great relationships with the guys here and definitely appreciate the support," Jones said. "But, it's about the team and what's best for the team. I know the guys will be ready to go. I know Tommy will be ready to go this week."South Korea lifts president's martial law decree after lawmakers reject military ruleStock market today: Losses for Big Tech pull US indexes lower Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business UpdatePurpleVine Drives TCL's Successful Entry into the HEVC Advance Patent Pool Leonardo DRS executive sells $784,810 in stockWhat's open and closed on Christmas Eve and Christmas Day 2024? None InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of DirectorsMartin O'Malley joins The LeadPONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace’s commercial efforts and play a pivotal role in driving the Company’s next phase of rapid innovation, strategic product commercialization, and growth. “I am thrilled to welcome Guy to the Treace team,” said John T. Treace, CEO, Founder and Board Member of Treace. “With a wealth of diverse medical technology industry experience, a demonstrated track record of strong customer engagement, leadership in innovation and product development, and a proven ability to deliver exceptional market growth, Guy is ideally suited to lead our commercial efforts.” “I’ve always admired and respected Treace, having watched the team create and lead in entirely new market segments,” said Mr. Guglielmino. “Treace has established a new standard with an approach that deeply understands their customers’ unmet needs, resulting in groundbreaking innovations that democratize the practice of the surgical treatment of bunions and midfoot deformities. I look forward to working with John and the Treace leadership team to deliver class-leading innovation, product commercialization, and sustained market performance.” Mr. Guglielmino joins Treace with deep medical technology industry expertise, having served in diverse senior leadership roles. Most recently, Mr. Guglielmino was President, Recovery Sciences at Enovis. Prior to that, he held senior Marketing roles at Enovis, Wright Medical, and at Bausch + Lomb. Mr. Guglielmino received his Bachelor of Science in Business & Entrepreneurship and his MBA from the Rochester Institute of Technology. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s expectations of innovation, product commercialization, market performance, and growth. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlateTM Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com . To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram . Contacts: Treace Medical Concepts Mark L. Hair Chief Financial Officer mhair@treace.net (904) 373-5940 Investors: Gilmartin Group Vivian Cervantes IR@treace.net
